<DOC>
	<DOCNO>NCT02227368</DOCNO>
	<brief_summary>To compare effect ticagrelor versus aspirin change peak walking time , evaluate grade treadmill test , one 26 week post-revascularization patient peripheral artery disease undergone endovascular revascularization moderate severe claudication ischemic rest pain .</brief_summary>
	<brief_title>Walking Effect Long Term Ticagrelor Subjects With PAD Who Have Undergone EVR</brief_title>
	<detailed_description>A Phase II Multicentre , Randomised , Double-Blind , Controlled , Parallel-Group Study Evaluate Walking Time Effect Long-Term Ticagrelor Comparison Long-Term Aspirin Administration Ambulatory Patients Peripheral Artery Disease Undergoing Endovascular Revascularization - The Ticagrelor Peripheral Artery Disease Endovascular Revascularization Study TI-PAD I EVR</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>Inclusion Criteria 1 . Written inform consent prior study specific procedure . 2 . Ambulatory male female outpatient age 50 year age old time Screening Visit . 3 . EVR , inguinal ligament include distal SFA and/or popliteal and/or tibial artery , plan occur within 5 week Screening Visit , determine clearly document Principal Investigator physician SubInvestigator ( MD/DO ) . Patients undergo proximal revascularization may enrol long procedure also include treat distal SFA , popliteal tibial artery . The EVR must confirm technically successful ( complete procedure haemostasis achieve ) patient randomise . 4 . Normal inflow low extremity determine Principal Investigator physician SubInvestigator ( MD/DO ) . Adequacy inflow assess hemodynamic measure , angiography image modality obtain Screening record medical record 30 day prior Screening Visit define imaging time procedure . A patient inadequate inflow time Screening still enrol inflow address resolve plan revascularization procedure . 5 . Diagnosis PAD confirm history one follow observe index ( intervention ) leg Screening Visit : 1 . Resting ABI ≤0.90 , 2 . In patient ABI &gt; 1.40 ( noncompressible vessel ) rest GTI &lt; 0.70 use inclusion . 6 . Patient advise beneficial effect smoke cessation exercise therapy process change smoke status exercise time Screening Visit . Exclusion Criteria 1 . Involvement plan and/or conduct study ( applies AstraZeneca staff and/or staff study site ) . 2 . Revascularisation plan treat proximal ( inflow ) disease iliac and/or common femoral artery . 3 . Previous randomisation present study . 4 . Participation another clinical study investigational product within last 3 month new clinical trial course study . 5 . Gangrene ischemic ulcer either low extremity . 6 . PAD nonatherosclerotic nature . 7 . Clinical necessity use dual antiplatelet therapy within 7 day prior randomisation , single antiplatelet therapy ( ticlopidine , prasugrel , vorapaxar , ticagrelor dipyridamole ) clopidogrel aspirin . Clopidogrel aspirin take include time load dose give . 8 . Clinical necessity use follow restrict concomitant medication within 4 week prior randomisation . Patients take medication Screening Visit may consider randomisation 4 week washout period medication . 1 . Pentoxifylline cilostazol relief claudication symptom 2 . Chronic oral parenteral anticoagulant therapy ( great 7 day ) 3 . Strong inhibitor CYP3A enzyme ( Section 5.6.9.1 ) 4 . Strong inducer CYP3A enzyme ( Section 5.6.9.2 ) 5 . Simvastatin lovastatin daily dose 40 mg 9 . Any disease process ( e.g . angina , cardiac abnormality , congestive heart failure ( CHF ) , chronic obstructive pulmonary disease ( COPD ) , respiratory disease , obesity , stroke , severe neuropathy foot , symptomatic musculoskeletal disease low extremity ) , PAD , would interfere exercise performance ETT prevent patient reach claudicationlimited PWT primary endpoint study . 10 . Coronary , aortic surgery , angioplasty , lumbar sympathectomy low extremity surgery impact ability walk treadmill within past 3 month prior EVR . Revascularization nonindex lower extremity within past 4 week prior EVR . 11 . Any major low limb amputation due PAD anticipate within next 3 month prior major amputation due PAD ( minor toe amputation allow interfere ambulation ) . 12 . Myocardial infarction stroke previous 3 month . 13 . Any concomitant disease process life expectancy le 1 year sufficiently severe compromise validity test performance . 14 . Dementia likely jeopardise understand information pertinent study conduct compliance study procedure . 15 . Concern inability patient comply study procedure and/or followup ( e.g. , alcohol drug abuse ) . 16 . Resting systolic blood pressure ≥180 mmHg diastolic blood pressure ≥95 mmHg Screening Visit , spite antihypertensive treatment allow protocol . 17 . A known bleeding diathesis , haemostatic coagulation disorder , systemic bleeding , whether resolve ongoing . 18 . Known severe liver disease ( e.g. , ascites clinical sign coagulopathy ) . 19 . Renal failure require dialysis . 20 . History previous intracranial bleed time , gastrointestinal bleed within past 6 month , major surgery within 30 day ( surgical wound judge associate increase risk bleed ) . 21 . History thrombocytopenia neutropenia . 22 . Hypersensitivity ticagrelor , aspirin lactose . 23 . Initiation antidiabetic , antihypertensive , lipidlowering betablocking drug within 1 month prior Screening Visit . 24 . Pregnancy , lactation , fertility without protection pregnancy ( woman childbearing potential ; urine serum pregnancy test perform Screening Visit ) .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Myocardial Infarction</keyword>
	<keyword>Peripheral Arterial disease</keyword>
	<keyword>Mycardial Ischemia</keyword>
	<keyword>Heart Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>Altherosclerosis</keyword>
	<keyword>Arteriosclerosis</keyword>
	<keyword>Arterial Occlusive Diseases</keyword>
	<keyword>Peripheral Vascular Diseases</keyword>
	<keyword>Ticagrelor</keyword>
	<keyword>Ticlopidine</keyword>
	<keyword>Platelet Aggregation inhibitor</keyword>
	<keyword>Hematologic Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Purinegic P2Y Receptor Antagonists</keyword>
	<keyword>Purinegic P2 Receptor Antagonists</keyword>
	<keyword>Purinergic Antagonists</keyword>
	<keyword>Purinergic Agents</keyword>
	<keyword>Neurotransmitter Agents</keyword>
	<keyword>Molecular Mechanisms Pharmacological Actions</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Fibrinolytic Agents</keyword>
	<keyword>Crardiovascular Agents</keyword>
</DOC>